Azole resistance in Aspergillus flavus and associated fitness cost
Mycoses · 2024
DOI: 10.1111/myc.13766 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, 2024. Verfasst von Elie Djenontin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unité de Parasitologie-Mycologie, Département de Virologie, Bactériologie-Hygiène, Parasitologie-Mycologie, CHU Henri Mondor, AP-HP, Créteil, France. Hauptthemen laut MEDLINE: Aspergillus flavus, Antifungal Agents, Drug Resistance, Fungal, Voriconazole. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
The resistance of Aspergillus flavus to the azole antifungal drugs is an emerging problem. Mutations in the molecular targets of the azole antifungals ‐ CYP 51 A, B and C ‐ are possible mechanisms of resistance, but data to confirm this hypothesis are scarce. In addition, the behaviour of resistant strains in vitro and in vivo is not yet understood.
Objectives
This study had 3 objectives. The first was to compare the sequences of CYP51 A, B and C in resistant and susceptible strains of A. flavus . The second was to look for the existence of a fitness cost associated with resistance. The third was to evaluate the activity of voriconazole and posaconazole on resistant strains in the Galleria mellonella model.
Methods
The CYP51 A, B and C sequences of seven resistant strains with those of four susceptible strains are compared. Fitness costs were assessed by growing the strains in RPMI medium and testing their virulence in G. mellonella larvae. In addition, G. mellonella larvae infected with strains of A. flavus were treated with voriconazole and posaconazole.
Results
In the CYP51A sequences, we found the A91T, C708T and A1296T nucleotide substitutions only in the resistant strains. The resistant strains showed a fitness cost with reduced in vitro growth and reduced virulence in G. mellonella . In vivo resistance to posaconazole is confirmed in a strain with the highest MIC for this antifungal agent.
Conclusions
These results allow to conclude that some substitutions in CYP51 genes, in particular CYP51A , contribute to resistance to azole drugs in A. flavus . The study of the relationship between drug dosage and treatment duration with resistance and the reduction of fitness costs in resistant strains is a major perspective of this study. This work could help to establish recommendations for the treatment of infections with resistant strains of A. flavus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unité de Parasitologie-Mycologie, Département de Virologie, Bactériologie-Hygiène, Parasitologie-Mycologie, CHU Henri Mondor, AP-HP, Créteil, France.
- UR Dynamyc UPEC, EnvA, ANSES. Faculté de Santé de Créteil, Créteil, France.
- UR7300 Stress Immunité Pathogène, Université de Lorraine, Vandoeuvre les Nancy, France.
- CHU de Bordeaux: Laboratoire de Parasitologie-Mycologie, CNR des Aspergilloses Chroniques, INSERM U1045: Univ. Bordeaux, Bordeaux, France.
- Université Grenoble Alpes, CNRS, Grenoble INP, CHU Grenoble Alpes, TIMC, Grenoble, France.
- Oniris, VetAgroBio Nantes, Nantes, France.
ORCID-Profile: Jacques Guillot
Zitieren
APA
Djenontin, E., Debourgogne, A., Mousavi, B., Delhaes, L., Cornet, M., Valsecchi, I., Adebo, M., Guillot, J., Botterel, F., & Dannaoui, E. (2024). Azole resistance in Aspergillus flavus and associated fitness cost. Mycoses. https://doi.org/10.1111/myc.13766
Vancouver
Djenontin E, Debourgogne A, Mousavi B, Delhaes L, Cornet M, Valsecchi I, et al. Azole resistance in Aspergillus flavus and associated fitness cost. Mycoses. 2024. doi:10.1111/myc.13766
BibTeX
@article{Djenontin2024,
author = {Djenontin, Elie and Debourgogne, Anne and Mousavi, Bita and Delhaes, Laurence and Cornet, Muriel and Valsecchi, Isabel and Adebo, Makiath and Guillot, Jacques and Botterel, Françoise and Dannaoui, Eric},
title = {Azole resistance in Aspergillus flavus and associated fitness cost},
journal = {Mycoses},
year = {2024},
doi = {10.1111/myc.13766}
}
EUVIMED